title: Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
abstract: OBJECTIVE
  To determine the effectiveness of cancer control afforded by radical prostatectomy (RP) in patients with clinical stage T3 prostate cancer.
  
  
  METHODS
  We retrospectively reviewed data for patients treated by RP for clinical stage T3 prostate cancer between 1995 and 2005. The following case characteristics were analysed: patient age, clinical presentation, preoperative prostate-specific antigen (PSA) level, Gleason score, tumour stage (2002 Tumour-Node-Metastasis), surgical procedure, pathological data, margin and lymph node status, and recurrence. Biochemical recurrence was defined as an increase in PSA level of >0.2 ng/mL after surgery. Kaplan-Meier survival curves were generated, and prognostic factors were evaluated.
  
  
  RESULTS
  Overall, 100 patients were included; only 79% of them had pT3 disease based on the pathological specimen. The median follow-up after RP was 69 months. The RP was open in 77 and laparoscopic in 23, with no significant difference between these approaches (P = 0.38). The 5-year PSA-free survival after surgery was 45%, and 5-year cancer-specific survival was 90%. On univariable analysis, Gleason score >7 (P = 0.01), pathological stage (pT2-T3a vs T3b) (P < 0.001), positive lymph node (P < 0.001), and positive margin (P < 0.001) were associated with recurrence. On multivariable analysis, lymph node, margin status and Gleason score were also significant (P < 0.05).
  
  
  CONCLUSIONS
  RP can be recommended as an alternative primary treatment that results in acceptable cancer control for clinical stage T3 prostate cancer in selected cases. However, the patient should be warned that surgery alone might not be sufficient to control the cancer, and that adjuvant therapy might be needed during the course of the disease.
authors.affiliation: Department of Urology, GHU EST (Pitiè-Tenon), Assistance-Publique Hôpitaux de Paris, Paris, France.
authors.forename: Evanguelos
authors.initials: E
authors.lastname: Xylinas
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Drouin
authors.forename: Eva
authors.initials: E
authors.lastname: Comperat
authors.forename: Christophe
authors.initials: C
authors.lastname: Vaessen
authors.forename: Raphaële
authors.initials: R
authors.lastname: Renard-Penna
authors.forename: Vincent
authors.initials: V
authors.lastname: Misrai
authors.forename: Marc-Olivier
authors.initials: MO
authors.lastname: Bitker
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Chartier-Kastler
authors.forename: François
authors.initials: F
authors.lastname: Richard
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
authors.forename: Morgan
authors.initials: M
authors.lastname: Roupret
mesh_terms: D000328:Adult; D000368:Aged; D004812:Epidemiologic Methods; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen